Our team attended the two-day First Congress on Advanced Regenerative Technologies in Kyiv—an event that brought together experts in the fields of regenerative medicine, tissue engineering, biomaterials, and reconstructive surgery.

The congress serves as an important platform for learning about the latest developments in cell and gene therapy, tissue regeneration, as well as modern approaches to personalized medical solutions. During the congress, Kateryna Osetrova and Mykhailo Pluzhnyk held a series of one-on-one meetings with leading experts, presenting product prototypes and a VR approach to their modeling. Presenting the product to leading industry experts is a crucial step toward bringing the product to market once certification is complete.

biodrook continues to move forward, developing technologies that shape the future of regenerative medicine.

biodrook is proud to announce that the company has been awarded the Seal of Excellence as part of the Seeds of Bravery program—an official distinction given to organizations with outstanding innovative potential, technical excellence, and a strategic vision for development.

This award confirms the high quality and significance of our work in the field of medical technology development, as well as our contribution to the development of Ukraine’s innovation ecosystem.

We are sincerely grateful to the experts and evaluators of the Seeds of Bravery program for their trust, support, and professional approach. This recognition strengthens our motivation to continue adhering to the highest standards of innovation, safety, and product quality.

By receiving the Seal of Excellence, biodrook has joined the community of European innovators and gained access to new opportunities for investment, acceleration, and partnerships within initiatives such as OnePass, Central Ukrainian EDIH, and the Enterprise Europe Network.

This achievement confirms our commitment to sustainable development, international cooperation, and the implementation of innovations in medical technologies.

The biodrook team, led by co-founder and CTO Mykhailo Pluzhnyk, participated in LOTOS—a large-scale event bringing together leading experts, scientists, and companies shaping the future of orthopedic and trauma surgery in Ukraine.

The event provided valuable networking opportunities in the field of 3D bioprinting and medical innovation. “Such meetings inspire and reinforce the belief that the development of future medicine is the result of collaboration.”

On October 1–3, one of the year’s key medical events—the Public Health Congress 2025—took place in Kyiv at the International Exhibition Center. The congress brought together doctors, managers, scientists, and representatives of the medical industry to discuss current challenges, exchange experiences, and present innovative solutions for the future of Ukraine’s healthcare system.

bidrook was honored to join this important event by participating in the professional dialogue. Our team paid special attention to participating in the conference on maxillofacial surgery—a timely, highly professional, and extremely interesting event within the forum.

We recognize the need for and importance of this field and are working to create innovative products for maxillofacial surgery that can address modern medical challenges and help patients.

Participating in the Public Health Congress 2025 was a valuable opportunity for us to exchange knowledge with colleagues and find new partners.

Our team was represented by Kateryna Osetrova and Mykhailo Pluzhnyk-Hladyr.

On September 4, 2025, the first international conference and exhibition Ukraine ReHealth 2025 took place in Kyiv at the Parkovy Congress and Exhibition Center—a key event dedicated to the restoration and modernization of Ukraine’s healthcare system following the full-scale invasion.

The event was organized by Impact Bridge LLC in collaboration with the law firm Sayenko Kharenko, the medical company Empirica, and the IT company Sigma Software, with the support of the Ministry of Health of Ukraine. Participants from across the country and international delegations gathered to discuss the extent of the damage, innovative technologies, attracting investment, and ways to build partnerships in the healthcare sector.

Biodrook attended the forum to participate in professional discussions, explore new trends in medicine, and assess the direction of Ukraine’s healthcare system. For us, it was a valuable opportunity to network with colleagues, hear the views of leading experts, and draw inspiration from international best practices.

Ukraine ReHealth 2025 reaffirmed its status as a strategic platform where ideas are formed, partnerships are built, and priorities for the future of medicine are defined.

A New Era of Responsibility and Trust in Medical Device Manufacturing

We are pleased to announce that biodrook has successfully obtained certification for compliance with the international standard DSTU EN ISO 13485:2018—one of the highest industry standards in the field of medical device design and manufacturing.

What is ISO 13485 and why is it important?

ISO 13485 is an international quality management standard specifically designed for medical devices. It regulates all stages of the product lifecycle: from design, development, and manufacturing to post-market monitoring, traceability, and user feedback.

Obtaining this certification means that biodrook’s manufacturing processes meet international safety and quality requirements, and all products undergo rigorous quality control and risk management procedures. biodrook has established a transparent system for documentation, change tracking, and accountability.

Why is this important for doctors, partners, clinics, and patients?

This certification is not just a formality. It is a guarantee of trust:

  • For clinics and doctors — confidence in the quality of implants and related solutions
  • For international partners — compliance with global requirements, simplification of import procedures and joint projects
  • For investors — confirmation of the maturity of internal processes and readiness

Digital Planning

Planning begins with CT or MRI scans and technical specifications from surgeons. A 3D model is created, tailored to clinical needs and the patient’s anatomy.

Regeneration-Supporting Material

biodrook uses a biodegradable composite based on polylactic acid (PLA) with added hydroxyapatite. The material has high biocompatibility and gradually degrades within the body.

3D printing technology

A key stage is the printing of custom products. Biodrook’s technology ensures geometric accuracy, porosity control, and structural stability.

Sterilization and quality control

After printing, the product undergoes low-temperature gas sterilization. Quality control checks: compliance with the geometric parameters of the 3D model, structural integrity, and compliance with medical standards.

Clinical Benefits

Custom biodegradable implants open up new possibilities in reconstructive orthopedics, traumatology, maxillofacial surgery, and potentially pediatric surgery.

The biodrook team has completed an important milestone in the implementation of innovative technologies in medical manufacturing—specialized training on the setup and maintenance of a 3D printer designed for the production of non-resorbable polymer implants made of polyetheretherketone (PEEK).

PEEK is a high-tech biocompatible material actively used in reconstructive surgery of the face and skull, as well as in neurosurgery. Thanks to its unique properties, particularly its mechanical characteristics similar to those of bone tissue, it allows for the creation of customized solutions for complex clinical cases.

The PEEK processing procedure requires working at extremely high temperatures and strict adherence to technical parameters. All stages—from equipment setup to product manufacturing—are documented in production protocols to ensure maximum precision, reproducibility, and minimization of production risks.

The training was conducted by Dr. Lukas Umfer (Graz, Austria), a leading expert with many years of experience in the production of implants for cranial reconstruction. His work is based on the Point-of-Care approach—the fabrication of custom implants directly at the medical facility, which reduces the time between surgical planning and the procedure itself.

For biodrook, this training was a key step in developing internal expertise and

The biodrook team is proud to announce that our project has been recognized as one of Ukraine’s 25 most promising tech startups by Forbes. This achievement underscores the importance of our mission—to create fast, accessible, and innovative solutions for regenerative medicine.

biodrook has focused its efforts on producing 3D-printed bone implants that transform into the patient’s own bone tissue. Our solutions will be valuable to medical institutions treating patients with bone defects, particularly among military personnel. Thanks to mobile and stationary production platforms, implant manufacturing time has been reduced to 48 hours, allowing us to quickly meet needs even in the most remote parts of the country.

The company continues to grow rapidly, preparing to launch large-scale production in Ukraine and enter international markets. Our partners, such as Biopharma, The Mount Sinai Health System, DSM, and EVONIK, support us in introducing innovative technologies in Ukraine and integrating them into the medical sectors of the EU and the U.S.

Biodrook is grateful to Forbes for its high recognition and support of innovative solutions that help transform medicine today and in the future. We will continue working to make medical technologies accessible to everyone who needs them.

Stay tuned for our updates, because

We are pleased to announce that Biodrook has reached an important milestone in its development by securing a reliable investor and launching production operations at the Biopharma facility.

We sincerely thank Kostyantyn Yefimenko, the head of Biopharma, for his trust and support during this important phase. His belief in our mission has been key to the creation and development of Ukrainian biotechnology production.

We also express our deep gratitude to our board of directors. Their experience and dedication have helped us reach this important milestone.

This achievement would not have been possible without the dedication and support of everyone who believed in Biodrook from the very beginning. We sincerely thank our colleagues, partners, and experts who have been with us on this challenging journey and shared our dreams and ambitions.

CONTACT US

info@biodrook.com

Start building the future of accessible biotechnology with biodrook today!